{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:01:52Z","timestamp":1767834112454,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T00:00:00Z","timestamp":1526688000000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["2U19 AI062629"],"award-info":[{"award-number":["2U19 AI062629"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["P30 GM103510"],"award-info":[{"award-number":["P30 GM103510"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["U54 GM104938"],"award-info":[{"award-number":["U54 GM104938"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["T32 AI007633"],"award-info":[{"award-number":["T32 AI007633"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008907","name":"OMRF J. Donald and Patricia Capra Fellowship","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008907","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008907","name":"OMRF Lou C. Kerr Chair in Biomedical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008907","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.vaccine.2017.05.006","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T11:08:51Z","timestamp":1494500931000},"page":"3416-3422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated"],"prefix":"10.1016","volume":"35","author":[{"given":"Eric K.","family":"Dumas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Garman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Cuthbertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassam","family":"Hallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata J.M.","family":"Engler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyamal","family":"Choudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Picking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith A.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Darise","family":"Farris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.05.006_b0005","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1146\/annurev.micro.55.1.647","article-title":"Anthrax","volume":"55","author":"Mock","year":"2001","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0010","first-page":"49","article-title":"Purification of factor I and recognition of a third factor of the anthrax toxin","volume":"26","author":"Stanley","year":"1961","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/n35101999","article-title":"Identification of the cellular receptor for anthrax toxin","volume":"414","author":"Bradley","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.05.006_b0020","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/j.1365-2958.1994.tb00500.x","article-title":"Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity","volume":"13","author":"Klimpel","year":"1994","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0025","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1073\/pnas.79.10.3162","article-title":"Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells","volume":"79","author":"Leppla","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.05.006_b0030","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1099\/00221287-22-1-206","article-title":"Purification of factors I and II of the anthrax toxin produced in vivo","volume":"22","author":"Stanley","year":"1960","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0035","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.mam.2009.06.002","article-title":"Anthrax toxins: a weapon to systematically dismantle the host immune defenses","volume":"30","author":"Tournier","year":"2009","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.vaccine.2017.05.006_b0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tim.2014.02.012","article-title":"Anthrax lethal and edema toxins in anthrax pathogenesis","volume":"22","author":"Liu","year":"2014","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0045","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3201\/eid0706.010604","article-title":"Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States","volume":"7","author":"Jernigan","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.006_b0050","first-page":"1","article-title":"Use of anthrax vaccine in the United States: recommendations of the advisory committee on immunization practices (ACIP), 2009","volume":"59","author":"Wright","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2017.05.006_b0055","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI0216204","article-title":"Development of an improved vaccine for anthrax","volume":"110","author":"Leppla","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2017.05.006_b0060","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/j.1365-2672.2007.03391.x","article-title":"A study of the physiology of Bacillus anthracis Sterne during manufacture of the UK acellular anthrax vaccine","volume":"103","author":"Charlton","year":"2007","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0065","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1016\/j.vaccine.2007.05.018","article-title":"Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine","volume":"25","author":"Hepburn","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.006_b0070","unstructured":"Biothrax. Fda. Gov. U.S. Food and Drug Administration, 5 Aug. 2016. Product insert."},{"key":"10.1016\/j.vaccine.2017.05.006_b0075","unstructured":"Anthrax Vaccine (Alum precipitated sterile filtrate). Mhra.gov.uk. Medicines and Healthcare Products Regulatory Agency, 23 Sept. 2016. Product insert."},{"key":"10.1016\/j.vaccine.2017.05.006_b0080","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2105\/AJPH.52.4.632","article-title":"Field evaluation of a human anthrax vaccine","volume":"52","author":"Brachman","year":"1962","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.vaccine.2017.05.006_b0085","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.006_b0090","doi-asserted-by":"crossref","first-page":"e13849","DOI":"10.1371\/journal.pone.0013849","article-title":"Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults","volume":"5","author":"Brown","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.05.006_b0095","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1128\/CVI.05556-11","article-title":"Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis","volume":"19","author":"Bellanti","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.3.5.4459","article-title":"Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults","volume":"3","author":"Campbell","year":"2007","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.006_b0105","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1128\/IAI.69.7.4509-4515.2001","article-title":"Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein","volume":"69","author":"Price","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.05.006_b0110","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1128\/iai.63.4.1369-1372.1995","article-title":"Protective immunity induced by Bacillus anthracis toxin-deficient strains","volume":"63","author":"Pezard","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.05.006_b0115","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.vaccine.2011.03.011","article-title":"Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity","volume":"29","author":"Crowe","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.006_b0120","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3201\/eid0810.020380","article-title":"Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen","volume":"8","author":"Quinn","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.006_b0125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2017.05.006_b0130","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/j.1462-5822.2006.00708.x","article-title":"Cytotoxic activity of Bacillus anthracis protective antigen observed in a macrophage cell line overexpressing ANTXR1","volume":"8","author":"Salles","year":"2006","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0135","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1462-5822.2005.00539.x","article-title":"Bacillus anthracis oedema toxin as a cause of tissue necrosis and cell type-specific cytotoxicity","volume":"7","author":"Voth","year":"2005","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0140","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.vaccine.2013.10.039","article-title":"Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial","volume":"32","author":"Wright","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.006_b0145","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/653495","article-title":"Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge","volume":"202","author":"Crowe","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.006_b0150","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/14760584.2015.981533","article-title":"Host immunity to Bacillus anthracis lethal factor and other immunogens: implications for vaccine design","volume":"14","author":"Altmann","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.05.006_b0155","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/CVI.00324-12","article-title":"A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques","volume":"19","author":"Quinn","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0160","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0165","doi-asserted-by":"crossref","first-page":"8410","DOI":"10.1016\/j.vaccine.2007.09.063","article-title":"Catalytically inactive anthrax toxin(s) are potential prophylactic agents","volume":"25","author":"Gupta","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.006_b0170","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/iai.52.2.356-363.1986","article-title":"Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity","volume":"52","author":"Turnbull","year":"1986","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.05.006_b0175","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.femsim.2004.05.011","article-title":"Characterization of the human immune response to the UK anthrax vaccine","volume":"42","author":"Baillie","year":"2004","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0180","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.mam.2009.08.006","article-title":"Anthrax vaccination strategies","volume":"30","author":"Cybulski","year":"2009","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.vaccine.2017.05.006_b0185","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1600-065X.2010.00969.x","article-title":"Progress and novel strategies in vaccine development and treatment of anthrax","volume":"239","author":"Chitlaru","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2017.05.006_b0190","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1574-695X.2011.00800.x","article-title":"The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax","volume":"62","author":"Brenneman","year":"2011","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.006_b0195","doi-asserted-by":"crossref","first-page":"e0148713","DOI":"10.1371\/journal.pone.0148713","article-title":"A comparison of the adaptive immune response between recovered anthrax patients and individuals receiving three different anthrax vaccines","volume":"11","author":"Laws","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.05.006_b0200","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1128\/IAI.00200-09","article-title":"Novel chimpanzee\/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody","volume":"77","author":"Chen","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.05.006_b0205","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/IAI.00261-07","article-title":"Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax","volume":"75","author":"Albrecht","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.05.006_b0210","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1016\/j.vaccine.2014.08.005","article-title":"Humoral responses to independent vaccinations are correlated in healthy boosted adults","volume":"32","author":"Garman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.006_b0215","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.1016\/j.vaccine.2010.07.075","article-title":"An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor","volume":"28","author":"Baillie","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:22:58Z","timestamp":1759400578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17306047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":43,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0264410X17306047"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}